Apply to trial NCT07813637

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Drug trial

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening